Table 3. Effect of Selenium Supplementation on TPO antibodies in Eight Randomized Clinical Trials.
Study | Selenium preparation | Outcome TPO-Ab | On L-T4 | No. of patients, placebo/selenium | Baseline Se, µg/L | Baseline TPO-Ab, kU/L |
---|---|---|---|---|---|---|
Gartner et al. (2002) [23] | Selenite | Fall | Yes | 34/36 | 69 | 904 |
Duntas et al. (2003) [24] | SeMet | Fall | Yes | 31/34 | 75 | 1,875 |
Turker et al. (2006) [25] | SeMet | Fall | Yes | 40/48 | - | 803 |
Karanikas et al. (2008) [26] | Selenite | No change | Yes | 18/18 | 75 | 524 |
Nacamulli et al. (2010) [27] | Selenite | No changea | No | 30/46 | - | 172 |
Eskes et al. (2014) [28] | Selenite | No change | No | 30/31 | 74 | 1,508 |
Pilli et al. (2015) [29] | SeMet | No change | No | 20/40 | 82 | 409 |
de Farias et al. (2015) [30] | SeMet | Fall | Yes | 27/28 | 37 | 1,009 |
TPO-Ab, thyroid peroxidase antibody; Se, selenium; Selenite, sodium selenite; SeMet, selenomethionine.
aFall at 1 year.